Nkarta logo

NkartaNASDAQ: NKTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 July 2020

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$174.30 M
-81%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
23%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 22 Nov 2024 23:41:10 GMT
$2.47-$0.02(-0.80%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NKTX Latest News

Why Nkarta Stock Is Soaring Today
fool.com14 August 2024 Sentiment: POSITIVE

Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
globenewswire.com13 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024.

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
globenewswire.com16 July 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings.

3 Undervalued Stocks Primed for a 2X Return
investorplace.com01 July 2024 Sentiment: POSITIVE

For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
globenewswire.com27 June 2024 Sentiment: POSITIVE

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
globenewswire.com13 June 2024 Sentiment: POSITIVE

Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science

Nkarta: Finally An Attractive Valuation
seekingalpha.com25 May 2024 Sentiment: POSITIVE

Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Seeking Alpha27 April 2024 Sentiment: NEGATIVE

NKTX has experienced a more than 50% decline from its peak in March 2024. The company is working on developing NKX019, a CAR-NK cell therapy that shows promise in treating cancer and autoimmune disorders. Initial data on NKX019 in oncology has been released, with more data expected in the middle of the year. The company has also begun exploring the potential of NKX019 in treating autoimmune diseases in the first half of 2024.

Nkarta to Participate in Upcoming Investor Conferences
GlobeNewsWire03 April 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:

3 Under-the-Radar Stocks Set to Soar 300% by 2026
InvestorPlace08 February 2024 Sentiment: POSITIVE

In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors.

What type of business is Nkarta?

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

What sector is Nkarta in?

Nkarta is in the Healthcare sector

What industry is Nkarta in?

Nkarta is in the Biotechnology industry

What country is Nkarta from?

Nkarta is headquartered in United States

When did Nkarta go public?

Nkarta initial public offering (IPO) was on 10 July 2020

What is Nkarta website?

https://www.nkartatx.com

Is Nkarta in the S&P 500?

No, Nkarta is not included in the S&P 500 index

Is Nkarta in the NASDAQ 100?

No, Nkarta is not included in the NASDAQ 100 index

Is Nkarta in the Dow Jones?

No, Nkarta is not included in the Dow Jones index

When was Nkarta the previous earnings report?

No data

When does Nkarta earnings report?

The next expected earnings date for Nkarta is 21 March 2025